KTTA

0.52

5.42% -0.0298

Vorhandelsmarkt: .52

Pasithea Therapeutics Corp (KTTA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.5498

Offen:

$0.5333

24-Stunden-Volumen:

320.07K

Relative Volume:

0.35

Marktkapitalisierung:

$17.38M

Einnahmen:

Nettoeinkommen (Verlust:

$-19.73M

KGV:

-0.2507

EPS:

-2.0742

Netto-Cashflow:

$-16.94M

1W Leistung:

-1.16%

1M Leistung:

-11.11%

6M Leistung:

-51.85%

1J Leistung:

-28.98%

1-Tages-Spanne:

$0.5003

$0.5599

1-Wochen-Bereich:

$0.47

$0.61

52-Wochen-Spanne:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Firmenname

Pasithea Therapeutics Corp

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

(702) 514-4174

Adresse

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KTTA Pasithea Therapeutics Corp	0.52	17.22M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten

Jul 01, 2026

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan

Jul 01, 2026

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Jun 30, 2026

Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa

Jun 30, 2026

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget

Jun 30, 2026

Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Jun 30, 2026

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Jun 30, 2026

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

Jun 29, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Jun 29, 2026

Jun 26, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW - TradingView

Jun 26, 2026

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Jun 23, 2026